Sabatolimab

Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells[1].

Product Specifications

CAS Number

[2252262-24-9]

Product Name Alternative

MBG453

UNSPSC

12352203

Target

Tim3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/sabatolimab.html

Purity

99.15

Solubility

H2O

Smiles

[Sabatolimab]

Molecular Weight

(144.675 kDa)

References & Citations

[1]Andrew M. Brunner, et al. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) : Updated Results from a Phase 1b Study. Blood (2020) 136 (Supplement 1) : 1–2.|[2]Schwartz S, et al., Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. Immunother Adv. 2022 Aug 10;2 (1) :ltac019.